SCHEMBL1852869

SCHEMBL1852869

O=c1[nH]c(CCl)nc2c1oc1ccc(Cl)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 15/20 0.67
CSNK2B P67870 14/20 0.67
PIM3 Q86V86 13/20 0.67
PIM2 Q9P1W9 13/20 0.67
CSNK2A2 P19784 13/20 0.67
CDC7 O00311 5/20 0.62
CSNK2A1 P68400 4/20 0.56
GSK3B P49841 2/20 0.56
DYRK1A Q13627 2/20 0.56
DYRK3 O43781 1/20 0.56
IGF1R P08069 1/20 0.56
CLK2 P49760 1/20 0.56
GSK3A P49840 1/20 0.56
PKN2 Q16513 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
CIT O14578 1/20 0.56
CYP1A2 P05177 1/20 0.56
CSNK2A3 Q8NEV1 1/20 0.56
TAOK3 Q9H2K8 1/20 0.56
ALDH1A1 P00352 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850855 0.86 PIM1 (0.69) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL1849748 0.83 PIM1 (0.82) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL1851306 0.83 PIM1 (0.70) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL1855348 0.82 ALDH1A1 (0.75) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL4573688 0.81 PIM1 (0.62) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL1852910 0.81 PIM1 (0.49) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL1852343 0.81 PIM1 (1.00) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL4594839 0.78 PIM1 (0.59) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL1849753 0.77 CDC7 (1.00) PIM1CSNK2BPIM3PIM2CSNK2A2
SCHEMBL13657347 0.77 PIM1 (0.74) PIM1CSNK2BPIM3PIM2CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 PIM1 1977/4885CSNK2B 350/4885PIM3 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.